Rational design and high-yield expression of SARS-CoV-2 nucleocapsid antigen for a sensitive and specific in-house ELISA Authors: Abbas Tazarghi, Mehdi Behrouzikhah, Hamidreza Abbasi, Mohsen Ebrahimi, Alijan Tabarraei, Ahad Yamchi, Hadi Razavi Nikoo Published: 2026 ABSTRACT BackgroundSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global pathogen with a high prevalence rate. Among diagnostic methods, serological assays have been effective for rapid screening and identifying a history of infection or vaccination. The nucleocapsid protein is the most conserved and immunogenic antigen of SARS-CoV-2, making it a key target for such tests. Although commercial kits are available for this purpose, a custom design with superior specificity, sensitivity, and accuracy can be both clinically and economically advantageous. In the present study, we designed a recombinant nucleocapsid protein (rNP) using a multi-parameter suite of bioinformatic approaches, including codon optimization, ribosomal binding site engineering, mRNA secondary structure analysis, and optimized expression of the final construct in an E. coli system. The purified rNP was then applied in an in-house ELISA to compare its overall diagnostic efficacy with that of a commercially available kit on a pool of 37 predetermined positive and 15 negative sera for SARS-CoV-2.ResultsResults showed that both assays were 100% specific, but the in-house design showed higher sensitivity (91.9% vs. 83.8%) and a greater area under the curve (0.94 vs. 0.84) compared to the commercial ELISA.ConclusionThis demonstrates that our optimized rNP production platform enables the development of a high-performance serological assay with superior diagnostic accuracy compared to a commercial alternative, providing a powerful and economical tool for surveillance and research in the post-pandemic era.Graphical Abstract Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), is an enveloped RNA virus belonging to the Coronaviridae family and the genus Betacoronavirus [1]. The virion contains a non-segmented, positive-sense, single-stranded RNA genome of approximately 30 kb, which is encapsulated within a helical nucleocapsid. This genome encodes a suite of structural, non-structural, and accessory proteins essential for the viral life cycle. Among these are four major structural proteins: spike (S), envelope (E), membrane or matrix (M), and nucleocapsid (N) [2]. The N protein is particularly abundant, with an estimated 1,000 copies per virion, where it plays a critical role in binding and packaging the viral RNA [3]. This multifaceted 419-amino-acid protein consists of two primary conserved and independently folded domains: an N-terminal domain (residues 44–176) and a C-terminal domain (residues 248–369) [4, 5]. Its molecular weight varies from 35 to 60 kDa, largely dependent on post-translational modifications [6]. Crucially for diagnostic applications, the N protein is highly conserved and immunogenic across SARS-CoV-2 variants, making it an ideal target antigen for serological assays [7]. Furthermore, recombinant N protein (rNP) produced in prokaryotic expression systems can adopt a highly ordered structure that preserves critical conformational epitopes, mirroring those found in the native virion [8]. While commercial kits are available, their cost and supply chain limitations can be prohibitive in resource-limited settings, highlighting the need for robust, in-house diagnostic alternatives. Given the diagnostic potential of the N protein, developing an economical and scalable production method is of significant interest. In this study, we employed sequence optimization strategies to enhance the expression of SARS-CoV-2 rNP in a prokaryotic system. Subsequently, we utilized the purified rNP to develop an in-house enzyme-linked immunosorbent assay (ELISA) for the detection of anti-N antibodies in clinical samples. The performance of our in-house assay, specifically its sensitivity and specificity, was then rigorously evaluated against a commercially available ELISA kit. Materials and methods Design and synthesis of the recombinant N protein expression construct The amino acid sequence of the SARS-CoV-2 N protein (GenBank accession no. YP_009724397.2) served as the template for designing a 1345 bp synthetic gene, which was optimized for maximal expression in Escherichia coli. The optimization process involved several in silico modifications. First, the coding sequence was codon-optimized based on the E. coli (strain K-12) codon usage frequency available from the Kazusa Codon Usage Database (available at https://www.kazusa.or.jp/codon/) [9]. This optimization aimed to improve key metrics, including the codon adaptation index (CAI), codon frequency distribution (CFD), and overall GC content, to better match the translational machinery of the host. Second, to enhance translation initiation, the region upstream of the start codon was re-engineered. The native ribosomal binding site (RBS) of the pET-9a vector was replaced with a synthetic RBS designed using the RBS Calculator software (Salis Lab) [10]. This was done to minimize the formation of inhibitory mRNA secondary structures in the vicinity of the translation start site. The stability of potential secondary structures throughout the full-length N protein mRNA was further assessed and minimized using the Vienna RNAfold web server (available at http://rna.tbi.univie.ac.at/) [11], and the likelihood of the protein solubility was predicted using the Protein-Sol server (available at https://protein-sol.manchester.ac.uk/) [12]. Finally, for downstream purification, a sequence encoding an N-terminal hexahistidine (6xHis) tag was incorporated immediately following the start codon. The final, fully optimized gene construct, flanked by XbaI and BamHI restriction sites, was commercially synthesized and sub-cloned into the corresponding sites of the pET-9a expression vector by Biomatik Co. (Canada). A schematic of the SARS-CoV-2 N protein and final expression construct is shown in Fig. 1. Fig. 1(a) Compartmental characteristics of the SARS-CoV-2 N protein with flanking regions recognized by XbaI and BamHI. (b) The final diagram of the N Protein construct assembled in the pET-9a expression vector (a) Compartmental characteristics of the SARS-CoV-2 N protein with flanking regions recognized by XbaI and BamHI. (b) The final diagram of the N Protein construct assembled in the pET-9a expression vector Expression and optimization of recombinant N protein in E. coli The pET-9a-N expression plasmid was transformed into chemically competent E. coli BL21 (DE3), which served as the host for protein expression. The transformation was performed using a standard heat-shock protocol, including a 30-min ice incubation, 45 s at 42 °C, 1-hour recovery in non-selective Luria-Bertani (LB) broth, after which the cells were plated on LB agar containing Kanamycin (50 µg/mL) and incubated overnight at 37 °C. The E. coli TOP10 strain was used for routine plasmid propagation. For protein expression, a single transformant colony of BL21 (DE3) cells was inoculated into LB broth containing Kanamycin (50 µg/mL) and grown overnight at 37 °C with vigorous shaking (180 rpm) to generate a starter culture. This starter culture was then diluted 1:100 into fresh LB medium, supplemented with Kanamycin (50 µg/mL) and 1% (w/v) glucose to suppress leaky expression. The culture was incubated at 37 °C while shaking (180 rpm) until the optical density at 600 nm (OD₆₀₀) reached the mid-logarithmic growth phase (0.6–0.8). A parallel culture of E. coli BL21 (DE3) transformed with an empty pET-9a vector was also grown and induced under the same conditions as a negative control. To determine the optimal conditions for protein expression, a matrix of parameters was systematically evaluated. Protein expression was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) at final concentrations of 0.1, 0.5, or 1.0 mM. Following induction, cultures were incubated at three different temperatures of 25 °C, 30 °C, and 37 °C. The expression level of the rNP was monitored over a 2−14-h time course, with samples collected at 2-h intervals for subsequent analysis. All expression trials were performed in triplicate. Purification and characterization of recombinant N protein Following induction, cell pellets were harvested by centrifugation at 6000 × g for 15 min at 4 °C and resuspended in a denaturing lysis buffer (50 mM NaH₂PO₄, 300 mM NaCl, 8 M Urea, pH 8.0) supplemented with an EDTA-free mini protease inhibitor cocktail (ROCHE cOmplete™). The cell suspension was lysed by sonication (2 mm probe, 5 cycles of 10 s on/10 sec off at 40% amplitude). The resulting lysate was clarified by centrifugation at 12,000 × g for 30 min at 4 °C. Analysis of the soluble (supernatant) and insoluble (pellet) fractions by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) confirmed that the overexpressed 6xHis-tagged rNP was sequestered in inclusion bodies. The inclusion body pellet from the 1 L culture preparation was thoroughly resuspended in 20−30 mL of fresh denaturing lysis buffer. The mixture was incubated for 1 h at room temperature (RT) with gentle shaking to ensure complete solubilization. The residual and non-solubilized materials were then removed by centrifugation (12,000 × g for 30 min at 4 °C), and the resulting supernatant was filtered (0.45 μm). The purification was performed using Nickel-Nitrilotriacetic Acid (Ni-NTA) affinity chromatography under conditions that facilitate on-column protein refolding. The clarified lysate was loaded onto a Ni-NTA agarose column pre-equilibrated with the lysis buffer. To refold the protein, the column was washed with a step-gradient of decreasing urea concentrations. This involved sequential washes (5 column volumes each) with buffers containing 7 M, 6 M, 4 M, 2 M, 1 M, and 0 M urea, all in a base buffer of 50 mM NaH₂PO₄, 300 mM NaCl, and 30 mM imidazole (pH 8.0). The fractions from these washes were pooled into two fractions (WB1 and WB2), and the refolded rNP was eluted from the column with an elution buffer (50 mM NaH₂PO₄, 300 mM NaCl, 250 mM imidazole, pH 8.0). To remove imidazole and exchange the buffer, the fractions containing the eluted rNP (EB1 and EB2) were dialyzed against PBS (pH 7.4) at 4 °C overnight using a dialysis tube with a 12–14 kDa molecular weight cutoff (CytoMatinGene, Cat. No. TUB2012). The dialysis buffer was changed three times during this period. The concentration of the purified rNP was then quantified using the Bradford assay [13], while its molecular weight and purity were assessed by 12% SDS-PAGE [14], followed by Coomassie Brilliant Blue staining and densitometry using ImageJ. For identity confirmation, a western blot was performed. Proteins were transferred to a nitrocellulose membrane, which was then blocked using 5% non-fat milk powder (w/v) in tris-buffered saline with 0.1% tween-20 (TBST). The membrane was subsequently incubated with a mouse anti-N protein primary antibody (1:1000; Santa Cruz Biotechnology, USA) overnight at 4 °C with gentle shaking. Following a series of washes with TBST, it was incubated with horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary antibody (1:2000; Sigma-Aldrich, Germany) for 1 h at 25 °C, also with gentle shaking. After a final series of washing with TBST, blots were visualized with 3,3′-Diaminobenzidine substrate. Human serum sample collection and processing This study utilized serum samples from a SARS-CoV-2-positive group (n = 37) and a negative control group (n = 15). The positive cohort consisted of 25 hospitalized patients and 12 outpatients, all with active SARS-CoV-2 infection confirmed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of nasopharyngeal or oropharyngeal swabs. To ensure inclusion of individuals with a robust infection, only patients with a quantification cycle (Cq) value below 30 were selected. The negative control cohort consisted of serum samples from asymptomatic individuals with negative RT-qPCR results collected contemporaneously between late 2020 and late 2021, a period characterized by the circulation of the early to intermediate SARS-CoV-2 variants in Golestan province, Iran. The study population (n = 52) had an average age of 58 years (30 males and 22 females). Clinical symptoms reported by the COVID-19-positive cohort included fever (n = 22), shivering (n = 18), shortness of breath (n = 12), sore throat (n = 10), coughing (n = 6), and chest pain (n = 2) (Table 1). This study was approved by the Ethics Committee of Biomedical Research at Golestan University of Medical Sciences (IR.GOUMS.REC.1398.396), and written informed consent was obtained from all participants prior to sample collection. Table 1Demographic and clinical information of the COVID-19 patients and healthy individuals involved in this studyVariablen (%)Age (years)Mean ± SD57.55 ± 5.63GenderMale30 (58%)Female22 (42%)Clinical statusHospitalized25 (48%)Outpatient12 (23%)Healthy15 (29%)Symptoms*Cough6 (16%)Fever22 (60%)Short of breath12 (33%)Sore throat10 (27%)Shivering18 (49%)Chest pain2 (6%)*Note: Symptoms were reported by the 37 COVID-19 positive participants Table 1Demographic and clinical information of the COVID-19 patients and healthy individuals involved in this studyVariablen (%)Age (years)Mean ± SD57.55 ± 5.63GenderMale30 (58%)Female22 (42%)Clinical statusHospitalized25 (48%)Outpatient12 (23%)Healthy15 (29%)Symptoms*Cough6 (16%)Fever22 (60%)Short of breath12 (33%)Sore throat10 (27%)Shivering18 (49%)Chest pain2 (6%)*Note: Symptoms were reported by the 37 COVID-19 positive participants Demographic and clinical information of the COVID-19 patients and healthy individuals involved in this study Age (years) Mean ± SD *Note: Symptoms were reported by the 37 COVID-19 positive participants Furthermore, to assess potential cross-reactivity, the assays were challenged with a panel of sera known to contain antibodies against other common respiratory pathogens, including human coronaviruses (OC43, 229E), respiratory syncytial virus, rhinovirus, adenovirus, and Epstein-Barr virus, each with two samples (total = 10). For all cohorts, ~ 5 mL of whole blood was collected from each participant via venipuncture. After allowing the blood to clot, serum was separated by centrifugation at 1,500 × g for 15 min at RT. To ensure biosafety, all serum samples were subsequently heat-inactivated at 56 °C for 30 min. Aliquots were prepared and stored at 4 °C for short-term use or at -70 °C for long-term storage. Development of an in-house indirect ELISA for anti-N IgG detection An indirect ELISA was developed and optimized to detect and quantify IgG antibodies specific to the SARS-CoV-2 N protein in human serum. High-binding 96-well microplates (Nunc, Denmark) were coated with 100 µL per well of the purified rNP, diluted to 2 µg/mL in a carbonate-bicarbonate coating buffer (pH 9.6). The plates were incubated overnight at 4 °C to facilitate antigen adsorption. Following incubation, the wells were washed thrice with phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBST), and blocked with 100 µL of blocking buffer (PBST containing 2% w/v bovine gelatin) and incubated for 2 h at 37 °C. After another wash cycle, dilutions of 1:500 heat-inactivated COVID-19 patients, respiratory panel, and negative control sera were prepared in PBS and added to the wells (100 µL/well) in triplicate followed by incubation for 2 h at 37 °C with gentle shaking. To account for the background signal, a parallel set of dilutions for each sample was also tested on uncoated but blocked wells. Following incubation with the primary antibody (serum), the plates were rewashed. Subsequently, 100 µL of an HRP-conjugated goat anti-human IgG secondary antibody (RaziBiotec AP8036), diluted 1:5,000 in blocking buffer, was added to each well and incubated for 1 h at 37 °C with shaking. After a final series of washes, the assay was developed by adding 100 µL of 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution (Sigma-Aldrich, T4444) to each well, and the colorimetric reaction was allowed to proceed for 30 min at room temperature in the dark. The reaction was then terminated by adding 50 µL of 2 N H₂SO₄ stop solution, and OD was measured at a wavelength of 450 nm using a microplate reader. The seropositivity for non-control samples was defined as the OD₄₅₀ value above the mean OD₄₅₀ of the negative control samples plus three standard deviations. The performance of this in-house ELISA, in terms of sensitivity and specificity, was subsequently compared against a commercially available anti-SARS-CoV-2 antibody detection kit (IDEAL Tashkhis Atieh, Iran, Cat. No: 7324-96). Statistical analysis All quantitative data are presented as the mean ± standard deviation of the mean unless otherwise specified. All statistical analyses were performed using SPSS Statistics (Version 22, IBM Corp., USA). For comparisons between multiple experimental groups, such as the optimization of protein expression conditions, a one-way ANOVA test was employed, followed by Tukey’s post hoc test for multiple comparisons to identify significant differences between specific groups. To evaluate the diagnostic performance of the in-house ELISA, a receiver operating characteristic (ROC) curve analysis was conducted. The area under the curve (AUC) was calculated to assess the overall diagnostic accuracy. The sensitivity and specificity of the in-house assay were determined at an optimal cutoff point derived from the ROC curve for the final clinical performance analysis. Finally, the agreement between the diagnostic outcomes of the in-house ELISA and the commercial ELISA kit was assessed using McNemar’s test. A p-value of less than 0.05 was considered statistically significant for all analyses. Results In silico optimization of the N protein gene for enhanced expression Following the multi-parameter in silico codon optimization strategy, the metrics critical for efficient translation of the N gene’s coding sequence in E. coli were significantly improved. The final optimized sequence featured a CAI of 0.91, a CFD of 91−100 quality value for 98% of codons, and an average GC content of 57.9%, all of which are ideal for the host’s translational machinery. Furthermore, the solubility of the resulting rNP in silico was predicted to yield a score of 0.63, which is considerably higher than the average score of 0.45 for proteins expressed in E. coli, suggesting a favorable likelihood of producing soluble protein (Fig. 2). Fig. 2Sequence optimization of the Nucleocapsid gene: (a) CAI demonstrates an average value of 0.91, which is far above the acceptable value of 0.8. (b) The ideal percentage range of GC content is between 30%−70%, and any peaks outside of this range will adversely affect the transcriptional and translational efficiency. The post-optimization average GC content for the sequence of interest was 57.90%, which largely fits within the optimal range. (c) The percentage distribution of codons is visualized in computed codon quality groups. The value of 100 is set for the codon with the highest usage frequency for a given amino acid in the desired expression organism. Codons with values lower than 30 are likely to hamper the expression efficiency. As shown, 98% of the optimized codons have a quality value of 90 to 100 in E. coli, which is largely optimal. (d) The predicted solubility of the rNP was calculated to be 0.63, presenting a computationally more desirable condition compared with the 0.45 average solubility Sequence optimization of the Nucleocapsid gene: (a) CAI demonstrates an average value of 0.91, which is far above the acceptable value of 0.8. (b) The ideal percentage range of GC content is between 30%−70%, and any peaks outside of this range will adversely affect the transcriptional and translational efficiency. The post-optimization average GC content for the sequence of interest was 57.90%, which largely fits within the optimal range. (c) The percentage distribution of codons is visualized in computed codon quality groups. The value of 100 is set for the codon with the highest usage frequency for a given amino acid in the desired expression organism. Codons with values lower than 30 are likely to hamper the expression efficiency. As shown, 98% of the optimized codons have a quality value of 90 to 100 in E. coli, which is largely optimal. (d) The predicted solubility of the rNP was calculated to be 0.63, presenting a computationally more desirable condition compared with the 0.45 average solubility In addition, reengineering of the translation initiation region showed that the synthetic RBS could result in a predicted ribosome-mRNA binding energy (ΔG) of -28.84 kcal/mol. This represents a substantial improvement in binding affinity over the pET vector’s native RBS (ΔG=-23.44 kcal/mol), promising more efficient translation initiation. The ΔG spacing, ΔG start, and ΔG mRNA of the optimized mRNA also revealed 0.00, -2.76, and − 24.39 kcal/mol, respectively, compared with the same parameters in the vector’s default sequence (0.29, -2.76, and 25.08 kcal/mol). Finally, the minimum free energy (MFE) of the optimized mRNA was calculated to be -388.49 kcal/mol, a notable decrease in stability of the potential secondary structures compared to the − 422.80 kcal/mol of the native sequence (Fig. 3). This reduction is predicted to enhance translational efficiency. Collectively, these computational modifications were designed to synergistically increase the overall yield of the rNP during bacterial expression. Fig. 3Secondary mRNA structures of the SARS-CoV-2 N protein in its native and optimized form, enriched with a comparison for MFE and various bioinformatic parameters for RBS design, including ΔG mRNA-rRNA (16 S), ΔG spacing, ΔG start, and ΔG mRNA. The results, particularly MFE, support the higher suitability of the optimized structure for transcription and translation Secondary mRNA structures of the SARS-CoV-2 N protein in its native and optimized form, enriched with a comparison for MFE and various bioinformatic parameters for RBS design, including ΔG mRNA-rRNA (16 S), ΔG spacing, ΔG start, and ΔG mRNA. The results, particularly MFE, support the higher suitability of the optimized structure for transcription and translation Optimization of recombinant N protein expression in E. coli Following the transformation of the optimized pET-9a-N construct into E. coli BL21 (DE3), initial expression trials confirmed the production of a protein band at the expected molecular weight for rNP (~ 46 kDa). However, solubility fractionation analysis revealed that the majority of the expressed rNP was sequestered in the pellet as inclusion bodies, with only a minor fraction remaining soluble in the supernatant (Fig. 4a). Surprisingly, this experimental finding did not align with our in silico prediction of favorable solubility. Following the systematic optimization of induction parameters, SDS-PAGE analysis of total cell lysates demonstrated a dose-dependent increase in rNP expression in various concentrations of IPTG, with significantly higher yields observed when induced with 0.5 mM and 1.0 mM IPTG compared to 0.1 mM (Fig. 4b). Furthermore, comparing post-induction temperatures (30 °C and 37 °C) showed that the highest expression levels were consistently achieved at 37 °C (Fig. 4c). Finally, time-course modifications identified that the accumulation of rNP peaked at ~ 10 h post-induction, with no substantial increase in yield at later time points (Fig. 4d). Combining these findings, a final volumetric yield of 20.8 mg/L of total rNP was achieved in shake flask cultures by induction with 1.0 mM IPTG at 37 °C for 10 h. Fig. 4Coomassie-blue stained 12% SDS‐PAGE analysis of the BL21 cell lysates containing rNP. a) Solubility analysis of the rNP shows the 10–100 kDa protein size marker (M), the pellet fraction of the cell lysate (P) with the greatest amount of rNP sequestered as inclusion bodies, and the supernatant fraction of the cell lysate (S) with a low yield of rNP in its soluble form. b) The expression of the rNP was tested at 0.1 M, 0.5 M, and 1 M of IPTG, with the third concentration leading to the most efficient expression. c) The incubation temperature used for rNP expression was shown to be more effective at 37 °C than 30 °C. d) The SDS-PAGE results show the 10-h time point as the most optimal incubation period Coomassie-blue stained 12% SDS‐PAGE analysis of the BL21 cell lysates containing rNP. a) Solubility analysis of the rNP shows the 10–100 kDa protein size marker (M), the pellet fraction of the cell lysate (P) with the greatest amount of rNP sequestered as inclusion bodies, and the supernatant fraction of the cell lysate (S) with a low yield of rNP in its soluble form. b) The expression of the rNP was tested at 0.1 M, 0.5 M, and 1 M of IPTG, with the third concentration leading to the most efficient expression. c) The incubation temperature used for rNP expression was shown to be more effective at 37 °C than 30 °C. d) The SDS-PAGE results show the 10-h time point as the most optimal incubation period Purification and immunochemical confirmation of recombinant N protein Given that the majority of the expressed rNP was located in inclusion bodies, the purification strategy under denaturing conditions with a urea-based buffer led to the exposure of N-terminal His-tags for binding to Ni-NTA resin columns. Following the gradual decrease of urea concentration, the refolded rNP was successfully eluted from the column, resulting in a final concentration of 4 mg/mL using the Bradford assay. The gel revealed a single, prominent band at the expected molecular weight of ~ 46 kDa, and the densitometric analysis indicated that the rNP in EB1 and EB2 fractions was ~ 81.1% and ~ 96.8% pure, respectively. Although less pure, EB1, which contained the highest concentration of rNP, was used for subsequent western blotting and the in-house ELISA development. Therefore, when transferred to a nitrocellulose membrane, the ~ 46-kDa protein band exhibited strong immunoreactivity against the commercially available mouse anti-N protein monoclonal antibody (Fig. 5). This confirmed that the purified protein was indeed the rNP with retained key antigenic epitopes following the purification and refolding process. Fig. 5Analysis of the pre- and post-chromatography fractions of rNP using 12% SDS-PAGE and western blotting. (a) From left to right, the molecular weight marker of 10–100 kDa (M), the unpurified total protein the BL21 cell lysate, fractions of rNP in the binding buffer (BB), pooled fractions of the washing buffer (WB1 and WB2, representing the 7, 6, 4 M and 2, 1, 0 M urea washes, respectively), fractions of the elution buffer with a high concentration of imidazole (EB1, the peak fraction; and EB2, the trailing fraction) revealing the purified rNP. (b) Western blotting of the purified protein with a mouse anti-N protein primary antibody detected and confirmed the presence of the rNP (∼45-kDa), paralleled with the molecular weight marker (M) Analysis of the pre- and post-chromatography fractions of rNP using 12% SDS-PAGE and western blotting. (a) From left to right, the molecular weight marker of 10–100 kDa (M), the unpurified total protein the BL21 cell lysate, fractions of rNP in the binding buffer (BB), pooled fractions of the washing buffer (WB1 and WB2, representing the 7, 6, 4 M and 2, 1, 0 M urea washes, respectively), fractions of the elution buffer with a high concentration of imidazole (EB1, the peak fraction; and EB2, the trailing fraction) revealing the purified rNP. (b) Western blotting of the purified protein with a mouse anti-N protein primary antibody detected and confirmed the presence of the rNP (∼45-kDa), paralleled with the molecular weight marker (M) Clinical performance evaluation of the in-house anti-N IgG ELISA The mean OD450 of the negative controls plus three standard deviation yielded a preliminary cutoff value of 0.20. The clinical performance of our in-house ELISA and its comparison with the commercially available ELISA kit were as follows: Clinical Sensitivity: When tested against the 37 positive serum samples, the in-house ELISA correctly identified IgG antibodies in 34 individuals, yielding a clinical sensitivity of ~ 91.9% (95% CI: 78.9% – 97.1%). In comparison, the commercial kit detected antibodies in 31 of the 37 patients, corresponding to a lower sensitivity of 83.8% (95% CI: 68% – 93.8%). The three samples missed by our in-house ELISA were a subset of the six samples missed by the commercial kit. Clinical Specificity and Cross-Reactivity: Both assays demonstrated excellent specificity for SARS-CoV-2-negative sera. Of the 15 healthy control samples, neither assay produced a false-positive result, yielding 100% specificity (95% CI: 81.5% – 100%). Moreover, no cross-reactivity was observed for either assay when tested against the panel of sera positive for other common respiratory pathogens outlined in Materials and Methods (Table 2). Table 2Comparison of in-house ELISA assay and commercial kit in detection of anti-rNP IgG antibodiesVirusClinical samplesAgreementCommercial kitIn-house ELISA assayNumberNumberNumberPositiveNegativePositiveNegativePositiveNegativeSARS-CoV-2371531153415 Table 2Comparison of in-house ELISA assay and commercial kit in detection of anti-rNP IgG antibodiesVirusClinical samplesAgreementCommercial kitIn-house ELISA assayNumberNumberNumberPositiveNegativePositiveNegativePositiveNegativeSARS-CoV-2371531153415 Comparison of in-house ELISA assay and commercial kit in detection of anti-rNP IgG antibodies Overall Diagnostic Accuracy: Following an ROC curve analysis to provide a comprehensive measure of overall diagnostic accuracy, the in-house rNP-based ELISA exhibited superior diagnostic performance, with an AUC of 0.94 (95% CI: 0.88–1). This was substantially higher than the AUC of 0.84 (95% CI: 0.72–0.96) observed for the commercial kit (Fig. 6). As a result, the final cutoff value for the in-house ELISA, as evaluated and confirmed by the ROC curve, was determined to be an OD450 of 0.20, providing an optimal balance between sensitivity and specificity. Fig. 6ROC curves for the in-house ELISA assay and commercial kit. The AUC was used as a measure of the sensitivity and specificity, indicating a greater area for the in-house ELISA assay compared to the commercial kit ROC curves for the in-house ELISA assay and commercial kit. The AUC was used as a measure of the sensitivity and specificity, indicating a greater area for the in-house ELISA assay compared to the commercial kit In addition, the McNemar’s test revealed no significant disagreement in the overall classification of positive and negative samples between the two assays (p = 0.25), though the in-house ELISA identified three additional positive samples missed by the commercial kit. Consequently, the superior overall diagnostic performance of the newly developed in-house assay is most clearly demonstrated by its substantially higher AUC value (0.94 vs. 0.84), enabling it to better distinguish between true positive and true negative samples across all diagnostic thresholds (Table 3). Table 3Diagnostic features of the in-house ELISA assay and commercial kit in detection of anti-rNP IgG antibodiesVirusIn-house ELISA assaySensitivity (%)Specificity (%)Accuracy (%)Positive predictive value (%)Negative predictive value (%)McNamara Test(p-value)TP1TN2FP3FN4SARS CoV-234150391.910094.210083.30.25 Commercial kit SARS CoV-231150683.810088.410071.4Sensitivity =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:$$\end{document}100Specificity =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:\:}\times\:$$\end{document}100Accuracy =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{o}\mathrm{t}\mathrm{a}\mathrm{l}\:\mathrm{S}\mathrm{a}\mathrm{m}\mathrm{p}\mathrm{l}\mathrm{e}\mathrm{s}}\times\:$$\end{document}100Positive predictive value =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:100$$\end{document}Negative predictive value =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:100$$\end{document}(1) TP: True Positive, (2) TN: True Negative, (3) FP: False Positive, (4) FN: False Negative Table 3Diagnostic features of the in-house ELISA assay and commercial kit in detection of anti-rNP IgG antibodiesVirusIn-house ELISA assaySensitivity (%)Specificity (%)Accuracy (%)Positive predictive value (%)Negative predictive value (%)McNamara Test(p-value)TP1TN2FP3FN4SARS CoV-234150391.910094.210083.30.25 Commercial kit SARS CoV-231150683.810088.410071.4Sensitivity =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:$$\end{document}100Specificity =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:\:}\times\:$$\end{document}100Accuracy =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{o}\mathrm{t}\mathrm{a}\mathrm{l}\:\mathrm{S}\mathrm{a}\mathrm{m}\mathrm{p}\mathrm{l}\mathrm{e}\mathrm{s}}\times\:$$\end{document}100Positive predictive value =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:100$$\end{document}Negative predictive value =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:100$$\end{document}(1) TP: True Positive, (2) TN: True Negative, (3) FP: False Positive, (4) FN: False Negative Diagnostic features of the in-house ELISA assay and commercial kit in detection of anti-rNP IgG antibodies Sensitivity =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:$$\end{document}100 Specificity =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:\:}\times\:$$\end{document}100 Accuracy =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{o}\mathrm{t}\mathrm{a}\mathrm{l}\:\mathrm{S}\mathrm{a}\mathrm{m}\mathrm{p}\mathrm{l}\mathrm{e}\mathrm{s}}\times\:$$\end{document}100 Positive predictive value =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{P}\mathrm{o}\mathrm{s}\mathrm{i}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:100$$\end{document} Negative predictive value =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}}{\mathrm{T}\mathrm{r}\mathrm{u}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:+\:\mathrm{F}\mathrm{a}\mathrm{l}\mathrm{s}\mathrm{e}\:\mathrm{N}\mathrm{e}\mathrm{g}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{v}\mathrm{e}\:}\times\:100$$\end{document} (1) TP: True Positive, (2) TN: True Negative, (3) FP: False Positive, (4) FN: False Negative Discussion The effective management of viral pandemics like COVID-19 relies on a dual diagnostic strategy: direct viral detection via molecular methods and indirect serological assessment of the host immune response. While RT-qPCR remains the gold standard for diagnosing active infections, its utility is constrained by factors such as cost, logistical complexity, and variable sensitivity depending on sample timing and quality [15]. Serological assays, such as ELISA, offer a complementary, scalable, and cost-effective solution for epidemiological surveillance, identifying past infections, and assessing vaccine immunogenicity. The SARS-CoV-2 N protein is an ideal target for such assays due to its high immunogenicity, relative conservation across variants, and abundant expression during infection [16]. This is particularly relevant for monitoring immune responses in populations immunized with inactivated whole-virus vaccines (e.g., Sinopharm and Covaxin), where anti-N antibodies are a key indicator of exposure or vaccination [17]. A cornerstone of this study was the development of a highly efficient prokaryotic expression platform for producing the rNP. Several N-protein-based ELISAs have reported variable and sometimes suboptimal sensitivity, a limitation that may stem from the quality or yield of the recombinant antigen [18]. We hypothesized that a multi-parameter in silico optimization of the N gene, encompassing codon usage, mRNA secondary structure, and RBS affinity, would synergistically enhance protein expression. Our results supported this hypothesis, culminating in a remarkable volumetric yield of total rNP. Even though eukaryotic systems are known to be advantageous for producing proteins requiring complex post-translational modifications, they often face challenges regarding scalability, production timelines, and cost compared to prokaryotic systems [19]. Given these factors, an optimized E. coli platform like the one we designed can still remain very efficient for the economical production of viral antigens for serological surveillance [20]. Nevertheless, a word of caution needs to be considered regarding the potential misfolding of recombinant proteins expressed in E. coli lineages. For instance, interestingly, while our in silico tools predicted a favorable likelihood of solubility, the protein was experimentally found to be sequestered in inclusion bodies. This highlights a common challenge in recombinant protein production, where current computational algorithms may not fully capture the complex biophysical factors governing protein folding in a non-native host. Despite this, purification from inclusion bodies under denaturing conditions is a robust and scalable method, and our high-yield production remains a significant advancement, as it enables the economical, large-scale manufacturing of a key diagnostic reagent, thereby improving the accessibility of serological testing. The utility of this high-quality rNP was demonstrated in our in-house indirect ELISA. The assay exhibited a clinical sensitivity of ~ 91.9% for detecting IgG antibodies in convalescent patient sera, a performance that was notably superior to the 83.8% sensitivity of the commercial kit used for comparison. Our assay’s sensitivity aligns with the higher end of performance reported for other N-based ELISAs, which have ranged from approximately 60% to 80% in similar patient cohorts [21]. Furthermore, our assay demonstrated 100% specificity, with no false positives among healthy controls. Critically, we observed no cross-reactivity with sera containing antibodies to other common human coronaviruses (HCoV-OC43, HCoV-229E) and other respiratory viruses. This lack of cross-reactivity with seasonal coronaviruses is a crucial attribute, as it minimizes the risk of false-positive results that can confound seroprevalence studies [22]. The superior overall diagnostic accuracy of our assay was quantitatively confirmed by its high AUC of 0.94 in the ROC analysis. Regarding the fraction selection, although EB2 exhibited a higher purity (~ 96.8%), the EB1 fraction was prioritized for ELISA coating due to its significantly higher antigen concentration. It provided a sufficient purity level (~ 81.1%) for the assay, indicating that the contaminants, while cannot be entirely ruled out as a potentially interfering factor, did not significantly interrupt antibody bindings as demonstrated by the aforementioned diagnostic parameters and low background signal observed. The landscape of SARS-CoV-2 serological diagnostics is vast, ranging from high-throughput, automated platforms like electrochemiluminescence immunoassays (ECLIA) to various ELISA formats and lateral flow assays (LFA). Automated ECLIA platforms (e.g., Roche Elecsys) are known for their high sensitivity and rapid processing times; however, they require expensive proprietary equipment, and their accuracy appears to be highly dependent on viral load [23, 24]. LFAs are also widely popular, inexpensive, and provide rapid qualitative diagnosis in less than 30 min; however, the existing evidence recommend that they may not be sufficiently reliable in clinical and epidemiological settings when high accuracy is a priority [25, 26]. In contrast, our in-house ELISA relies on standard, widely available laboratory equipment, offering a scalable alternative without compromising diagnostic accuracy. In addition, when compared to other N-protein-based assays reported in the literature, our assay outperforms their sensitivity and specificity ranging from ~ 70−90% and ~ 90−100%, respectively [23, 27–29]. While platforms like ECLIA and LFA may offer marginal speed improvements, our N-protein-based ELISA provides an effective diagnostic tool that is particularly well-suited for large-scale epidemiological monitoring and vaccine immunogenicity assessment in settings where a balance between cost and high performance is sought. Despite these promising findings, the limitations of our study must be acknowledged. The primary limitation is the relatively small sample size used for clinical validation (n = 37 COVID-19 patients, n = 15 healthy controls) and the lack of differential data on the assay’s reactivity in symptomatic and asymptomatic patients. Secondly, precise clinical data regarding the specific phase of the disease at the time of sample collection, as well as detailed demographic data, such as gender and age distribution for the individual cohorts are missing. Additionally, while our samples were collected during a period when the early to intermediate variants were prevalent, genomic sequencing was not performed on individual patient samples; therefore, we cannot definitively correlate the ELISA performance with specific SARS-CoV-2 variants. Furthermore, although our in-house ELISA demonstrated ~ 91.9% sensitivity, three samples from the positive cohort were identified as false negatives. These three samples, since also missed by the commercial kit, may have been collected within the early days of symptom onset or belonged to individuals with mild disease, suggesting that the anti-N IgG levels may not have reached the threshold of detection yet [29, 30]. The samples may also have been mishandled [31], or the pertaining patients been infected with variants undetectable by both assays. It is notable because studies have shown that mutations in the receptor-binding domain of the spike protein can alter the antigen-antibody kinetics [32], a phenomenon that may similarly affect the N protein as well and lead to false negative outcomes. Moreover, our cross-reactivity panel included only the five most common respiratory viruses in a relatively small group as mentioned. Therefore, larger, longitudinal cohorts with well-characterized symptom onset dates, detailed demographic information, variant tracking, and a broader array of pathogens will be essential to provide a more granular understanding of the assay’s diagnostic performance in diverse public health settings. In conclusion, this study successfully outlines a rational design and optimization strategy for the high-yield production of SARS-CoV-2 rNP in E. coli. We leveraged this antigen to develop and validate an in-house ELISA that demonstrates superior sensitivity and excellent specificity compared to a commercial alternative. This work provides a robust and economical platform for the development of serological tools essential for ongoing COVID-19 surveillance and research. This allows us to bypass the intrinsic costs hidden in commercially available alternatives, such as marketing, import tariffs, distribution logistics, and supply-chain markups, resulting in a significantly reduced cost per plate and better adaptability to reginal public health needs.